Functional characterization of the colorectal cancer metastasis microbiome
The METABAC project aims to investigate the functional roles of bacteria in colorectal cancer metastasis using innovative platforms to uncover their impact on cancer progression and potential therapeutic targets.
Projectdetails
Introduction
Host cells and microbial inhabitants form an intricate ecosystem in the human body, extensively influencing host phenotypes in health and disease. Despite much progress in sequencing-based cancer microbiome research, elucidating functional roles of bacteria in metastasis formation remains an important unsolved challenge. In the METABAC project, we will explore such bacterial roles as drivers of colorectal cancer metastasis. We will investigate new concepts on whether bacteria can equip cancer cells with malignant features, migrate within the host, and potentially represent targets for cancer therapy.
Aim 1: Characterization of Microbial Inhabitants
In Aim 1, my group will characterize the microbial inhabitants of colon tumors and metastases. We will uncover bacterial species and their genetic features in metastases by using:
- Sequencing-based approaches
- Imaging-based approaches
- Culturing-based approaches
Aim 2: Mechanistic Dissection of Bacterial Impacts
In Aim 2, we will mechanistically dissect functional impacts of metastasis-derived bacteria on distinct stages of the metastatic process. For this, we will use specialized platforms that we have pioneered, including:
- Organoid platforms
- Organ chip platforms
- Orthotopic organoid-bacteria co-engraftment platforms
Aim 3: Bacterial Migration and Tropism
In Aim 3, uncovering the tropism, timing, and routes of bacterial migration to different metastasis sites takes center stage. Bacterial strains and organoids derived from different metastasis sites will be co-engrafted into mice and traced to:
- Lymph node metastases
- Liver metastases
- Lung metastases
Conclusion
The METABAC project will provide an unprecedented characterization of microbial roles in metastasis. Our combination of metastasis-derived bacterial strains with novel organoid, organ chip, and in vivo platforms puts us in a unique position to close the gap between cancer microbiome sequencing and mechanistic studies and promises groundbreaking functional insights into host-microbe interactions in cancer and beyond.
Financiële details & Tijdlijn
Financiële details
Subsidiebedrag | € 1.499.894 |
Totale projectbegroting | € 1.499.894 |
Tijdlijn
Startdatum | 1-10-2024 |
Einddatum | 30-9-2029 |
Subsidiejaar | 2024 |
Partners & Locaties
Projectpartners
- DEUTSCHES KREBSFORSCHUNGSZENTRUM HEIDELBERGpenvoerder
Land(en)
Vergelijkbare projecten binnen European Research Council
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Functional cartography of intestinal host-microbiome interactionsThe project aims to elucidate gut microbiome-host interactions through advanced spatial profiling, predicting disease onset and identifying biomarkers for IBD and CRC. | ERC Synergy ... | € 10.382.670 | 2024 | Details |
Systematic Triangulation of Pathobiont-Host-InteractionsThe project aims to identify disease-driving pathobionts linked to genetic risk factors in IBD and CRC using high-throughput technology and machine learning to enhance precision medicine. | ERC Starting... | € 1.993.688 | 2024 | Details |
Resolving metabolic interactions between the gut microbiota and the host with multi-omics-based modellingThis project aims to systematically characterize gut bacteria interactions and their metabolic contributions to host health using experimental and computational methods, enabling targeted microbiota interventions. | ERC Starting... | € 1.499.323 | 2024 | Details |
Microbiome-based diagnostics and therapeuticsThis project aims to develop microbiome-based diagnostic and therapeutic products by leveraging multi-omics data to identify predictive bacterial strains for disease onset and progression. | ERC Proof of... | € 150.000 | 2023 | Details |
Transcriptional REGUlation as a mediator of bacterial interactions in the microBIOMEREGUBIOME aims to elucidate transcriptional regulation in gut bacteria responses to environmental stimuli, enhancing understanding of their impact on host health and identifying targets for microbiota modulation. | ERC Starting... | € 1.496.479 | 2023 | Details |
Functional cartography of intestinal host-microbiome interactions
The project aims to elucidate gut microbiome-host interactions through advanced spatial profiling, predicting disease onset and identifying biomarkers for IBD and CRC.
Systematic Triangulation of Pathobiont-Host-Interactions
The project aims to identify disease-driving pathobionts linked to genetic risk factors in IBD and CRC using high-throughput technology and machine learning to enhance precision medicine.
Resolving metabolic interactions between the gut microbiota and the host with multi-omics-based modelling
This project aims to systematically characterize gut bacteria interactions and their metabolic contributions to host health using experimental and computational methods, enabling targeted microbiota interventions.
Microbiome-based diagnostics and therapeutics
This project aims to develop microbiome-based diagnostic and therapeutic products by leveraging multi-omics data to identify predictive bacterial strains for disease onset and progression.
Transcriptional REGUlation as a mediator of bacterial interactions in the microBIOME
REGUBIOME aims to elucidate transcriptional regulation in gut bacteria responses to environmental stimuli, enhancing understanding of their impact on host health and identifying targets for microbiota modulation.
Vergelijkbare projecten uit andere regelingen
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Mapping the mycobiomeDit project ontwikkelt en valideert een innovatieve detectiemethode voor het mycobiome in de darm, met als doel de rol ervan in gezondheid en ziekte te begrijpen en therapeutische strategieën te verbeteren. | Mkb-innovati... | € 155.400 | 2015 | Details |
Mapping the mycobiome
Dit project ontwikkelt en valideert een innovatieve detectiemethode voor het mycobiome in de darm, met als doel de rol ervan in gezondheid en ziekte te begrijpen en therapeutische strategieën te verbeteren.